- Dec 3, 2017
- Reaction score
- Political Leaning
The vaccine ARCoV uses the same revolutionary technique as the Pfizer-BioNTech and Moderna products, and early trials suggest it may prove just as effective.
- The vaccine ARCoV uses the same revolutionary technique as the Pfizer-BioNTech and Moderna products, and early trials suggest it may prove just as effective
- Work on a production facility in Yunnan province started last year and developers hope to produce over a hundred million doses a year
The vaccine – which uses the same advanced revolutionary techniques as the drugs developed by Pfizer-BioNTech and Moderna – is at the end of phase 2 human trials and will start large-scale phase 3 trials next month, Ying Bo, founder and chief executive of Suzhou Abogen Biosciences, told China National Radio.
The vaccine, known as ARCoV, has been jointly developed by Abogen, the Academy of Military Science and Walvax Biotechnology.
Keep your eye on mRNA technology. It's a wave of the future in medicine, not just for vaccines but for other medical applications.